Welcome to our dedicated page for Senti Biosciences Holdings SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senti Biosciences SEC filings document a clinical-stage biotechnology issuer built around the Gene Circuit platform and its cell-therapy pipeline. The company’s 8-K reports cover operating and financial results, corporate updates, clinical or regulatory disclosures, shareholder voting matters, governance items, capital-structure matters and material agreements, including research-and-development laboratory lease disclosures.
The filing record also includes a Form 15-12G for Senti Biosciences, Inc. after a completed Delaware holding company reorganization under which Senti became a subsidiary within Senti Biosciences Holdings. That filing addresses termination or suspension of Exchange Act registration and reporting duties for the covered Senti common stock, alongside the issuer’s corporate-status and security-class disclosures.
Senti Biosciences, Inc. plans a tax-free holding company reorganization, targeted to become effective by April 16, 2026. The company would merge into a new subsidiary, with Senti Biosciences Holdings, Inc. becoming the successor issuer.
Each existing share of Senti common stock would automatically convert into an equivalent share of Senti Biosciences Holdings common stock with the same rights. Shares would continue trading on the Nasdaq Capital Market under the symbol SNTI with a new CUSIP number, and stockholders are expected not to recognize gain or loss for U.S. federal income tax purposes. Directors, officers, assets, businesses and operations would remain the same after the reorganization, though the company may decide not to complete it or could delay completion.
New Enterprise Associates 15, L.P. and affiliated entities report an updated ownership position in Senti Biosciences, Inc. They beneficially own 3,775,615 shares of Senti’s common stock, representing 12.1% of the outstanding shares based on 31,144,497 shares outstanding as of March 19, 2026. The filing states that this Amendment No. 3 is being made because their percentage ownership decreased by more than 1% due to an increase in Senti’s shares outstanding, not because of recent share sales or purchases. NEA 15 acquired the shares for investment purposes and may buy or sell additional shares in the future depending on market conditions and its evaluation of the company, but it currently has no specific plans for corporate actions such as mergers, board changes, or major asset sales.
Senti Biosciences, Inc. is a clinical-stage biotech company developing gene circuit–enabled cell and gene therapies, with a primary focus on oncology. Its lead program, SENTI-202, is an off-the-shelf CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
In a Phase 1 trial, SENTI-202 showed a 50% overall response rate in twenty AML patients, with 42% achieving complete remission or CRh and most remissions being MRD-negative at the recommended Phase 2 dose. The FDA granted SENTI-202 Orphan Drug and RMAT designations, reflecting its potential in a high‑need setting.
The company is expanding its pipeline using a modular gene circuit platform (Logic Gating, Multi-Arming, Regulator Dials, Smart Sensors) across NK, T cells, and gene therapy modalities, and maintains collaborations with partners such as BlueRock Therapeutics and Celest Therapeutics, plus multiple NCI license agreements. As of March 19, 2026, Senti had 31,144,497 common shares outstanding and a non‑affiliate market value of approximately $53.2 million as of June 30, 2025.
Senti Biosciences, Inc. reported 2025 results and highlighted key clinical progress, led by SENTI-202 in relapsed or refractory acute myeloid leukemia. The program generated updated positive preliminary Phase 1 data with encouraging response rates, durability and a favorable safety profile, and received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
As of December 31, 2025, Senti Bio held $16.4 million in cash and cash equivalents, with total assets of $51.2 million and total liabilities of $45.6 million. For full-year 2025, research and development expenses were $37.6 million and general and administrative expenses were $26.2 million. The company recorded a net loss of $61.4 million, or $2.73 per share, including a non-recurring $5.1 million impairment of long-lived assets and $5.7 million of non-cash stock-based compensation.
Senti Biosciences, Inc. entered into a series of agreements to restructure its facility lease and related sublease for its Alameda, California premises. Effective September 1, 2025, the company will reduce its leased space from approximately 91,910 to 45,955 rentable square feet, cutting its proportionate share of operating expenses and taxes to 50% while keeping responsibility for all utilities until the surrendered space is re-let.
The amended lease sets stepped monthly base rent for the remaining premises, starting at $188,311 from September 1, 2025 through July 31, 2026 and rising over time to $293,010 for August 2022. As consideration for this rent reduction, the landlord may draw $2.0 million on the company’s existing $2.76 million letter of credit, after which the required letter of credit amount drops to $760,000.
The company also amended its sublease with GeneFab, LLC so the subleased space and GeneFab’s payment obligations mirror the amended lease economics, and entered into a consent and letter agreement. GeneFab will pay a $1.0 million reduction fee to the landlord and has $1,374,005 of outstanding base rent that can be satisfied through a prepayment credit for future work or services, with any unpaid portion due by September 1, 2026. GeneFab’s failure to perform on these obligations constitutes an immediate event of default under the amended sublease.
Senti Biosciences executive Kanya Rajangam reported a routine tax-related share disposition. On this filing, 10,757 shares of common stock were withheld by the company to cover income tax obligations tied to vested restricted stock units, and not sold on the open market. After this withholding, Rajangam directly holds 74,843 common shares.
Senti Biosciences CEO Timothy K. Lu reported a tax-related share disposition. On the net settlement of time-based restricted stock units, 80,666 shares of common stock were withheld by the company to cover income tax obligations and remittance, which the filing states is not an open market sale. After this withholding, Lu directly holds 639,583 common shares, and the filing also notes 52,839 shares held indirectly, including through the Luminen Trust, where he disclaims beneficial ownership except for any pecuniary interest.
Senti Biosciences officer reports tax share withholding from RSU settlement. On 02/02/2026, Pres. & Chief Med. & Dev. Officer Kanya Rajangam had 1,384 shares of Senti Biosciences common stock withheld at a price of $0 per share to cover income tax obligations on vested restricted stock units.
These shares were withheld by the company and the transaction did not involve an open market sale. Following this tax-related withholding, Rajangam directly beneficially owns 85,600 shares of Senti Biosciences common stock.
Senti Biosciences CEO Timothy K. Lu reported a routine tax-related share withholding. On February 2, 2026, the company withheld 4,191 shares of common stock to cover income tax obligations tied to vested restricted stock units, which was not an open market sale.
After this withholding, Lu directly beneficially owned 720,249 shares of common stock. The filing also lists 52,839 shares held indirectly by his spouse and another 52,839 shares held by Luminen Services, LLC as trustee of the Luminen Trust, for which Lu disclaims beneficial ownership except for any pecuniary interest.
Celadon Partners SPV 24 and Celadon Partners, LLC report a 45% beneficial stake in Senti Biosciences, Inc. common stock, including warrant shares subject to a 45% cap. They report beneficial ownership of 13,511,322 shares, which includes 3,734,322 shares issuable upon exercise of warrants, calculated against 26,290,838 shares outstanding as of October 31, 2025.
The investors state they are in preliminary discussions with Senti about a potential financing of at least $10.0 million through convertible bonds issued by a new Senti subsidiary. These bonds would be convertible into equity of the subsidiary or exchangeable for Senti common stock, with proceeds intended to advance CMC and clinical trials for v2.0 process development and GMP manufacturing. They are also exploring possible restructuring or merger and acquisition transactions with Senti that could involve changes to the company’s capital structure. The investors report no Senti stock transactions in the past 60 days.